Kevin L. Carter

11/21/2013

The treatment of cancer is evolving from a largely reactive, empirical approach to a proactive one in which genomic information is used to improve diagnostic accuracy, guide therapeutic choices, and improve patient outcomes.

The treatment of cancer is...

11/21/2013

First Report Managed Care

Development of Electronic Prior Authorization Has Reached an Inflection Point

05/24/2012

Kevin L. Carter ;

San Francisco—“With the possibility of radical changes in the way pharmacy benefits are administered and delivered, the development of electronic prior authorization (ePA) has reached an inflection point, and the industry needs to work...

San Francisco—“With the...

05/24/2012

First Report Managed Care

Inhibition of HIV-1 Disease Progression

12/17/2012

Kevin L. Carter ;

Two important human lentiviruses have been described: (1) pandemic HIV type 1 (HIV-1), and (2) HIV type 2 (HIV-2), which is mainly confined to West Africa. Both viruses have similar transmission routes, cellular targets, and AIDS-defining...

Two important human lentiviruses...

12/17/2012

First Report Managed Care

Department

Randomized Controlled Trials of Biologics for Rheumatoid Arthritis

04/26/2012

Kevin L. Carter ;

Disease-modifying antirheumatic drugs for rheumatoid arthritis have been considered effective treatments that can reduce or prevent joint damage.

Disease-modifying antirheumatic...

04/26/2012

First Report Managed Care

Patterns of Antiamyloid-β Antibodies in Typical and Atypical Alzheimer Disease

08/16/2012

Kevin L. Carter ;

A major feature of Alzheimer disease (AD) is the deposition of brain amyloid-β (Aβ) peptide. IgG antibodies directed to Aβ naturally occur in the elderly, and their serum and cerebrospinal fluid levels may be significantly altered in the...

A major feature of Alzheimer...

08/16/2012

First Report Managed Care

Conference Insider

Place-of-Service Management for Infusible Drugs

05/24/2012

Kevin L. Carter ;

San Francisco—Infliximab, a monoclonal antibody against tumor necrosis factor alpha (TNFα), is used to treat autoimmune conditions such as psoriasis, Crohn’s disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and...

San Francisco—Infliximab, a...

05/24/2012

First Report Managed Care

Repeat Lipid Testing in Patients with Coronary Heart Disease

10/23/2013

Kevin L. Carter ;

Based on Adult Treatment Panel III guidelines, it is common current practice to suggest annual lipid testing in patients with coronary heart disease (CHD). Those with abnormal lipid levels are suggested to receive intensified treatment. For...

Based on Adult Treatment Panel...

10/23/2013

First Report Managed Care

Management Strategies for Febuxostat as Chronic Therapy for Gout

05/24/2012

Kevin L. Carter ;

San Francisco—Gout affects as many as 5 million people in the United States and is the most common cause of inflammatory arthritis for men >40 years of age in the US. Traditionally, the goals of treatment for this condition have been to...

San Francisco—Gout affects as...

05/24/2012

First Report Managed Care

Older Patients with Mantle-Cell Lymphoma

12/17/2012

Kevin L. Carter ;

The long-term prognosis for older patients with mantle-cell lymphoma is poor. Only a minority of patients have a complete remission, and relapse or progression usually occurs within 2 to 3 years, resulting in an overall survival of <5...

The long-term prognosis for...

12/17/2012

First Report Managed Care

Feature

Literature-Based Genetic Risk Scores and Cardiovascular Disease Events in Women

05/05/2010

Kevin L. Carter ;

Risk prevention in cardiovascular disease (CVD) has improved in recent years as genomewide association studies have found possible genetic and molecular markers (especially those in the 9p21 region) that are directly associated with CVD. But...

Risk prevention in...

05/05/2010

First Report Managed Care